Comprehensive Comparison of a Genotype-Forward vs. Phenotype-Forward Approach for Monogenic Cardiovascular Diseases in the UK Biobank Cohort
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Monogenic cardiovascular diseases (MCVD) remain substantially under-diagnosed, and thus interest is shifting from a phenotype-forward approach towards a genotype-first strategy that applies to population-wide genomic screening. We evaluated the prevalence of pathogenic and predicted pathogenic MCVD variants and assessed disease expression in the population-based UK Biobank (UKB) cohort to determine whether yield is greater in phenotype-versus genotype-forward approach.
Methods
Pathogenic and likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) predicted to be pathogenic (pp-VUS) in 47 MCVD genes were assessed. In the genotype-forward approach, UKB participants with P/LPs or pp-VUS were assessed for symptoms of disease using electronic health record (EHR) interrogation, emulating a clinical approach to population-based screening. In the phenotype-forward approach, participants with stricter EHR-based evidence of disease expression were identified (emulating current clinical care) and the presence of P/LPs and pp-VUS was determined.
Results
Following QC, 467,850 participants were included. Overall, 1 in 125 participants in UKB carry an MCVD P/LP. In the genotype-forward approach, 3,709 (0.79%) participants carried an MCVD P/LP and 42.1% of these had symptoms of the associated MCVD; another 29,269 (6.3%) carried a pp-VUS with 21.5% of these having symptoms of disease. In the phenotype-forward approach, 62,488 (13.4%) expressed an MCVD using strict evidence of disease expression and of these individuals 1% carried an associated P/LP variant and 2.4% carried an associated pp-VUS.
Conclusion
We show here that a genotype-forward approach leads to a 2.5 times higher diagnostic yield (3.6 times higher when considering pp-VUS) compared with the phenotype-forward approach, which missed 936 P/LP carriers with disease symptoms. While cost, access and ethics need to be considered, these results support expanded population-based genetic screening to improve diagnosis of potentially treatable MCVD.
